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ABSTRACT 
Plasmodium falciparum malaria has the highest death toll of all human parasitic diseases and 
nearly half of the global population is living at risk of infection. Reducing the malaria burden 
with the goal of achieving elimination will require sustained commitment for control and 
better monitoring tools that can guide efforts to limit transmission. An effective malaria 
vaccine could significantly accelerate progress towards elimination but incomplete 
understanding of malaria immunity hampers vaccine development. Antibodies are key 
components of immunity to malaria and can also serve as sensitive markers of exposure. Data 
on the dynamics and specificity of the antibody response in natural P. falciparum infection 
could improve our understanding of the acquisition and maintenance of immunity, and be 
used to develop better serological tools for transmission surveillance. 
In study I, we examined the temporal trends in malaria transmission over a period of 25 years 
in a closely monitored population in a rural area in Tanzania. We detected a gradual reduction 
in parasite prevalence starting prior to large-scale interventions and found that evaluation of 
spleen rate and haemoglobin levels were complementary to microscopy and molecular 
methods for estimates of malaria burden in this area of initially very high transmission. In 
study II, we developed new models for serological surveillance of malaria transmission based 
on cross-sectional data on age-specific antibody levels and evaluated their performance by 
further examining the transmission trends observed in study I. We demonstrated that these 
models are robust and improve precision in serological transmission estimates based on 
cross-sectional antibody data. In study III, we conducted a longitudinal follow-up of 
travellers treated for malaria in Sweden. We provided quantitative estimates of the dynamics 
and the longevity of malaria-specific antibodies and antibody secreting cells in absence of re-
exposure. In study IV, we examined the antibody responses to 111 P. falciparum antigens in 
the longitudinally followed travellers and identified novel candidate serological markers of 
recent exposure that warrant further evaluation. Together these studies contribute to our 
overall understanding of the acquisition and maintenance of the antimalarial antibody 
response. The results help to improve current methods for serological malaria transmission 
surveillance and provide new information on antibody responses to P. falciparum that should 
be explored as markers of exposure.  
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1 INTRODUCTION 
1.1 MALARIA 
Malaria is a mosquito-borne potentially life-threatening disease caused by protozoan parasites 
of the genus Plasmodium (1). The main six species that cause disease in humans are 
Plasmodium falciparum, P. vivax, P. malariae, P. ovale spp. (P. ovale curtisi and P. ovale 
wallikeri), and P. knowlesi (2). Plasmodium knowlesi is a monkey malaria parasite of 
Southeast Asian macaques that is able to infect humans (3). The burden of malaria falls 
predominantly on sub-Saharan Africa where more than 90 per cent of the 216 million cases 
(95% confidence interval [CI]: 196–263) occurred in 2016 (1). This thesis focuses on  
P. falciparum, which is estimated to be responsible for more than 90 per cent of all malaria 
related morbidity and mortality (Figure 1) (4). 
	
Figure	1.	Spatial	distribution	of	P.	falciparum	infection	prevalence	in	African	children	(age	2-10)	in	2015.	
(Malaria	Atlas	Project	(5),	available	from:	https://map.ox.ac.uk,	reproduced	with	permission).	 	
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1.1.1 The parasite and its life cycle 
The P. falciparum parasite is a complex organism with a large genome, containing 
approximately 5300 genes distributed across fourteen chromosomes. The parasite requires 
two fundamentally different hosts to complete its life cycle. The female Anopheles mosquito 
is the disease vector and the definitive host, in which the parasite reproduces sexually, and the 
human is the intermediate host where asexual reproduction occurs (Figure 2) (6). 
 
 
Figure	2.	The	life	cycle	Plamsodium	falciparum	(Su	et	al.	2007	(7),	reproduced	with	permission	from	Nature	
publishing	group).	
Infection in the human host is initiated when a female Anopheles mosquito injects saliva 
containing P. falciparum sporozoites into the skin of the human during a blood meal (6). The 
motile sporozoites migrate to the liver where proteins on the surface of the sporozoite, e.g. 
circumsporozoite protein (CSP), mediate binding and invasion of liver cells (8). Following 
liver cell invasion the parasite undergoes asexual development and replication over a period 
of approximately 5-15 days. This process generates up to 40,000 parasite daughter cells, so 
called merozoites (9). This part of the life cycle, which is clinically silent, is referred to as the 
pre-erythrocytic stage of infection. At the end of this stage, a merosome, i.e. a form of 
parasite filled vesicle, bud off from the infected liver cell and transports the merozoites to the 
blood stream (10). Here, the merosome ruptures and the merozoites are released (11). The 
blood stage of infection is subsequently initiated when a merozoite invades an erythrocyte 
through a rapid but complex process (12,13). There is a high degree of redundancy in the 
mechanisms by which the merozoite can invade the erythrocyte and the parasite may utilise 
alternative pathways. Briefly, the process begins with an initial contact between the 
merozoite and the erythrocyte, in which merozoite surface proteins (MSP) are likely to play 
an important role (13). The remainder of the process requires regulated secretion of proteins 
to the merozoite surface from specialised apically located secretory organelles (14).  
Ookinete
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After an apical re-orientation of the merozoite, a tight irreversible attachment is formed to the 
erythrocyte with the involvement of two parasite protein families, the erythrocyte binding 
antigens (EBA) and the reticulocyte binding protein homologues (RH). The interaction 
between RH5 and basigin on the erythrocyte surface has been demonstrated to be essential 
for erythrocyte invasion (15). The reorientation and attachment is followed by the formation 
of a moving junction, in which apical membrane antigen 1 (AMA-1) interact with rhoptry 
neck proteins (RON), thereby mediating entry of the parasite into the erythrocyte (16,17). 
Within the erythrocyte the parasite undergoes asexual development and replication during a 
period of approximately 48 hours after which the erythrocyte ruptures, releasing around 20 
daughter merozoites. These merozoites go on to invade new erythrocytes, thereby 
establishing a cyclic blood-stage infection where parasite numbers increase exponentially 
with the completion of each cycle (18). A small proportion of merozoites are triggered to 
undergo sexual development after erythroycte invasion (6). This leads to the formation of 
male and female gametocytes that can be ingested by blood feeding Anopheles mosquitos. 
Within the midgut of the mosquito, the haploid male and female gametocytes develop into 
gametes and fuse to form a diploid zygote that further differentiates into a motile ookinete 
(6). The ookinete traverses the mosquito midgut wall, forming an oocyst within which 
haploid sporozoites develop. The oocyst ruptures, releasing new sporozoites that migrate to 
the mosquito salivary gland from where they can be transmitted to a human host (19). 
1.1.2 Pathogenesis 
Symptoms of malaria occur only during the blood stage of the infection (20,21). A key 
component in the pathogenesis during P. falciparum infection is the ability of the parasite to 
express its own proteins on the surface of the infected erythrocyte (22). These proteins are the 
so called variant surface antigens, among which P. falciparum erythrocyte membrane  
protein 1 (PfEMP-1) is the most well described (23). Towards the end of each asexual blood 
stage cycle, these proteins, particularly PfEMP-1, mediate the binding of the infected 
erythrocytes to deep vasculature endothelial cells (sequestration) and to uninfected 
erythrocytes (rosetting). Thereby the infected erythrocytes avoid entering the spleen where 
they would otherwise be destroyed (24,25). However, sequestration within the deep 
vasculature of the brain, heart, liver, lungs, kidney, subcutaneous tissues, and during 
pregnancy within the placenta, leads to microvasculature obstructions and consequently to 
reduced tissue blood flow and oxygen delivery causing local inflammation and tissue damage 
(26,27). During the blood stage of infection a strong systemic inflammatory response, similar 
to that observed in bacterial sepsis, is also induced (28). Multiple parasite pathogen-
associated molecular pattern molecules trigger inflammation through pattern recognition 
receptors, e.g. toll-like receptors, on a wide range of innate immune cells (29–32). This early 
immune activation causes a massive production and release of pro-inflammatory cytokines, 
e.g. interleukin (IL) IL-1β, IL-6, IL-8, IL-12, interferon-γ (IFN-γ), and tumour necrosis 
factor-α (TNF-α) (33–35). Furthermore, both parasite erythrocyte destruction and 
inflammation-induced suppression of erythropoiesis contribute to the development of 
malarial anaemia (36). 
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1.1.3 Clinical presentation and treatment 
Fever is perhaps the most classical symptom of malaria, but the clinical presentation of  
P. falciparum infection may range from severe life-threatening syndromes to asymptomatic 
carriage of infection. Disease severity depends on a large number of host and pathogen 
factors, e.g. prior immunity, age, genetic resistance, parasite virulence, duration of infection 
etc. (37,38). In non-immune individuals infection with P. falciparum is almost always 
symptomatic. Patients often present with intermittent fever and non-specific symptoms, e.g. 
headaches, malaise, abdominal pain, muscle aches and diarrhoea (39). In absence of prompt 
diagnosis and treatment the disease can progress to a severe and complex life-threatening 
syndrome affecting multiple organ systems. Children, pregnant women, and individuals with 
immunosuppression or chronic diseases (e.g. diabetes) are at highest risk of severe disease 
(12,40). The clinical signs and symptoms of severe disease include (but are not limited to) 
prostration, impaired consciousness and coma, convulsions, shock, hypovolaemia, 
tachypnoea and respiratory distress, hypoxia, hypoglycaemia, jaundice and hemoglobinuria 
(41). Particularly in children, severe malaria can be categorised into three main syndromes,  
i) cerebral malaria, of which the hallmark symptoms are unrousable coma and multiple 
convulsions, ii) severe malarial anaemia (haemoglobin levels <5 g/dL), and iii) metabolic 
acidosis (41,42). In uncomplicated (i.e. non-severe) malaria the recommended first line 
treatment consists of an artemisinin based combination therapy (ACT). In addition to a 
full course of ACT, severe cases should also be treated with intravenous injections of 
artesunate (39). 
1.2 ACQUIRED IMMUNITY TO MALARIA 
In areas where P. falciparum transmission is high or moderate, disease incidence is highly 
age-dependent. Severe and life-threatening disease occurs primarily in children less than five 
years of age. Incidence of clinical malaria declines gradually with age, reflecting the gradual 
acquisition of immunity (Figure 3) (43). Immunity to clinical malaria is acquired slowly with 
repeated infections and requires continuous exposure in order to be maintained (Reviewed in: 
Marsh 2006, Langhorne 2008 and Crompton 2014) (20,44,45). In high transmission areas 
immunity to the most severe forms of disease is acquired roughly within the first five years of 
life. Individuals remain susceptible to less severe forms of febrile malaria until late childhood 
or early adolescence. Thereafter they acquire the ability to control also the milder forms of 
the disease and therefore seldom experience symptoms of clinical malaria. However, 
complete resistance to infection is rarely if ever achieved, and also in high endemic areas 
asymptomatic blood-stage infections remain common in individuals of all ages (46).  
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Figure	3.	Schematic	representation	of	the	relative	age-specific	incidence	of	severe	malaria,	mild	malaria	and	
asymptomatic	P.	falciparum	infection	in	individuals	living	in	a	malaria	endemic	area.	(Langhorne	et	al.	2008	
(45),	reproduced	with	permission	from	Nature	Publishing	Group).	
1.2.1 Antibodies and their role in protection against clinical malaria 
Antibodies are critical components of the naturally acquired protective immune response to 
malaria and are particularly important during the blood stage of the infection. This was 
demonstrated already in the 1960’s through the seminal work of Cohen et al. in which 
transfer of immunoglobulin G (IgG) from highly immune Gambian adults to children with 
acute clinical malaria was shown to limit disease severity and lead to rapid parasite clearance 
and resolution of symptoms (47). Important targets for immunity appear to include antigens 
on both the surface of the merozoite and on the infected erythrocyte (48,49). Parasite specific 
antibodies are likely to mediate protection through multiple mechanisms. For example, 
binding of antibodies to merozoite surface and secreted proteins may block erythrocyte 
invasion pathways and merozoite growth (50), inhibit parasite egress from schizonts (51), 
promote merozoite lysis due to complement activation (52), and stimulate phagocytosis and 
neutrophil respiratory burst attack through opsonisation (53,54). Furthermore, antibody 
binding of parasite proteins on the surface of infected erythrocyte may prevent sequestration, 
stimulate phagocytosis of infected erythrocytes as well as mediate agglutination of infected 
erythrocytes, thereby improving splenic clearance (55,56). 
High titre antibody response to a large number of parasite antigens (including MSPs, and 
members of the EBA and RH protein families) have been correlated with clinical protection 
in cohort studies (48,57,58). However, discriminating responses that reflect a high degree of 
prior exposure from those actually mediating protection have proven difficult and robust 
serological correlates of protection are currently lacking. Identifying such correlates would 
require a detailed characterisation of the functional basis, as well as the target epitopes, of any 
protective effect associated with the magnitude of an antigen-specific antibody response 
(53,54,59,60).  
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1.2.2 Acquisition and maintenance of antibody mediated immunity 
In general terms, antibody mediated immunity to malaria requires the acquisition of sufficient 
levels of high-affinity inhibiting antibodies that are maintained over time. Circulating 
antibodies are produced by antibody secreting cells (ASCs), which are terminally 
differentiated cells of B-cell lineage, specialised in antibody secretion. The ASCs can be 
divided into two distinct categories i) short-lived ASCs (short-lived plasma cells/plasma 
blasts) and ii) long-lived ASCs (long-lived plasma cells) (61–63). Although, the short-lived 
ASCs are responsible for the bulk of the antibody secretion during and shortly after infection, 
the longevity of an antibody response is primarily determined by the generation and survival 
of long-lived ASCs (63–65). These long-lived ASCs reside in the bone marrow or secondary 
lymphoid organs where they continue to secrete antibodies for the duration of their life (64). 
Because of the physical niches they occupy, the long-lived ASCs are difficult to study. 
However, the numbers of ASCs in the bone marrow are highly correlated with the levels of 
circulating antibodies (66,67), and modelling of longitudinal antibody data using an antibody 
dynamics model has been used to estimate the dynamics of antibodies and both short- and 
long-lived ASCs (68). Memory B-cells are also important for the antibody-mediated 
immunity and respond rapidly to new infections by efficiently proliferating and 
differentiating in to ASCs (69–71). It has been demonstrated that malaria-specific memory B-
cells can be maintained independently of antibody responses for several years in the absence 
of re-exposure (72,73). 
For many viral and bacterial infections, protective and long-lived antibody responses are 
acquired after a single exposure (74). In contrast, the acquisition of antibody mediated 
immunity to malaria requires multiple repeated infections (20,44). Although protective 
antibodies are acquired with time, the process is remarkably slow (47,75,76) and the antibody 
response appears to be comparatively short-lived, particularly in children (68,77,78). The 
reasons for the slow acquisition of immunity remain incompletely resolved but several 
mechanisms have been proposed. Given the redundancy in host-cell invasion pathways (13), 
the high degree of antigen polymorphisms (79), and the clonal variation in erythrocyte 
surface antigens (23), it has been suggested that a large number of genetically diverse 
infections would be required to induce an antibody response with sufficiently broad 
specificity to provide protection (20). However, there is growing evidence that the immune 
environment induced during acute P. falciparum may be sub-optimal for the induction of a 
high quality and long-lived immune response. Impaired T-cell help and germinal centre 
formation (80,81) lead to a dysregulation of the B-cell response, with preferential induction 
of short-lived ASCs and the generation of so called atypical memory B-cells hampering 
development of both long-lived ASCs and immune memory (82–84). 
Although, the antimalarial antibody response is often considered short-lived, the dynamics of 
antibodies and ASCs in response to infection remain poorly described and only a few studies 
have provided quantitative estimates on the longevity of antibodies (77,78) or ASCs (68).  
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The dynamics of the response is likely to be antigen-specific and, in addition to prior 
exposure, also depends on a large number of individual-specific immune factors that govern 
the response longevity (85). A detailed characterisation of the antigen-specific dynamics of 
antibodies and ASCs, and of the individual and exposure related factors that determine the 
longevity of the response, could greatly improve our understanding of the acquisition and 
maintenance of antibody mediated immunity (75,86). 
1.2.3 Malaria vaccines 
The fact that functional and protective antibody responses are acquired following both natural 
and experimental infections has inspired efforts to develop a highly effective malaria vaccine 
(47,87,88). Despite its sophisticated immune evasion mechanisms, the parasite exposes large 
numbers both polymorphic and conserved proteins to the immune system (57). As described 
above, many of these proteins are involved in processes that are essential for the survival of 
the parasite, e.g. host-cell binding and invasion, and either have been or could be considered 
as candidate antigens for a malaria vaccine (88,89). Despite years of research, a highly 
protective vaccine is yet to be developed. Several approaches and potential vaccines based on 
different stages of the parasites life cycle are currently being explored. Among these there are 
i) pre-erythrocytic vaccines that aim to protect humans from acquiring infections all together, 
ii) blood-stage vaccines that aim to limit parasite replication, facilitate clearance and reduce 
the severity of disease manifestations, and iii) so called transmission blocking vaccines, 
targeting the sexual stages of the parasite, with the aim to prevent transmission back to 
mosquitoes (90,91). 
A limited number of candidate vaccines representing each of these stages are currently 
undergoing clinical trials (92). Pre-erythrocytic vaccines in clinical trials are either whole 
sporozoite vaccines or subunit vaccines. The whole sporozoite vaccines consist of either live 
attenuated sporozoites or live sporozoites given under chemoprophylactic treatment (93–95). 
The most advanced malaria vaccine to date, RTS,S is a subnunit vaccine based on the 
sporozoite protein CSP. Despite a limited efficacy, pilot implementation of the RTS,S will  
be initiated in three African countries during 2018 (96,97). Several blood-stage antigens  
(e.g. MSP-1, MSP-2, MSP-3, and glutamate rich protein) have previously been evaluated as 
candidate subunit blood stage vaccines but with limited success (88). Currently clinical trials 
are ongoing for RH5, which is a leading blood stage vaccine candidate, and AMA-1 as well 
as for PfEMP-1_VAR2CSA, a vaccine candidate specifically aimed at preventing pregnancy-
associated malaria (92,98,99). The transmission blocking subunit vaccines currently being 
evaluated are based on sexual stage antigens PfS25 or PfS230 (92,100). Malaria vaccine 
responses in many cases appear to decay rapidly over time. For RTS,S, vaccine efficacy 
waned rapidly as antibody levels declined (97). Vaccine development would be greatly 
accelerated by a better understanding of the dynamics of the immune response, including a 
better understanding of the factors that determine the response longevity (85,86,101).  
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1.3 EPIDEMIOLOGY AND CONTROL 
A highly effective malaria vaccine would greatly improve the prospects for control and 
eventual elimination of malaria (102,103). In absence of such a vaccine, the cornerstones of 
malaria control are still i) vector control, ii) prevention of disease in “at-risk” populations 
through chemoprophylaxis, iii) rapid and accurate diagnosis and treatment of malaria, and  
iv) sustained malaria surveillance (5). 
Distribution of insecticide treated bed nets (ITNs) is the most widely adopted strategy for 
vector control and is highly accepted as ITNs also provide personal protection for the 
individuals using them (104). Other vector control strategies include indoor residual spraying 
(IRS) with insecticides and the use of larvicides to kill mosquito larvae and the pupae (105). 
Protection of at-risk individuals through chemoprophylaxis has previously mainly been 
practiced in the form of intermittent preventive treatment during pregnancy (IPTp) to reduce 
placental malaria, anaemia, neonatal mortality and low birth weight (106,107). However, 
since 2012, seasonal malaria chemoprevention has also been recommended for children aged 
3-59 months living in areas of highly seasonal malaria transmission (1). Malaria rapid 
diagnostic tests (RDTs) have been implemented to improve access to accurate malaria 
diagnostics and furthermore, the prompt use of ACTs for treatment has been widely promoted 
(39,108). 
Since year 2000 there has been a substantial reduction in the global malaria burden with an 
estimated reduction of more than 50 per cent in both prevalence of infection and clinical 
malaria incidence (1,5,109). It has been estimated that the global scale-up in malaria control 
activities have contributed to averting 663 million cases (credible interval [CrI]: 542– 753) of 
malaria between 2000 and 2015. The greatest effect in reducing transmission has been 
attributed to the use of ITNs which have been estimated to account for 68 per cent (CrI: 62-
72%) of the reduction (5). Due to the overall reduction in transmission, several countries are 
currently approaching a state where malaria elimination appears feasible (110,111). However, 
despite the overall encouraging reduction in disease transmission, not all countries experience 
the same positive trends. Fifteen countries are currently estimated to account for 
approximately 80 per cent of all malaria cases globally, with Nigeria and the Democratic 
Republic of Congo accounting for 27 and 10 per cent of all cases, respectively (1). 
Furthermore, there are worrying reports of a widespread mosquito-resistance to the 
pyrethroid-containing insecticides that are used on ITNs and for IRS (112), as well as of the 
emergence of parasites resistant to ACT in Southeast Asia (113).  
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1.4 MONITORING MALARIA TRANSMISSION INTENSITY 
In order to further reduce the global malaria burden and actually achieve regional  
elimination, sustained high quality transmission monitoring and disease surveillance are 
imperative (114–116). Due to the complex transmission cycle of P. falciparum, involving 
both the human and the mosquito, actually quantifying the intensity of transmission is far 
from trivial. Various surrogate metrics have traditionally been used to estimate the 
transmission intensity of P. falciparum (Reviewed in Tusting et al. 2014) (117). 
Among others, these metrics include evaluation of spleen rate and parasite prevalence in 
children (2–10 years old), estimates of malaria disease incidence, entomological inoculation 
rates (EIR), and the force of infection (FOI). All of these metrics are subject to varying 
degrees of uncertainty specifically related to the data on which they are based. 
Evaluation of the spleen rate (i.e. the proportion of a population with palpable spleen 
enlargement) was the first method established for estimating the burden of malaria 
transmission (118,119). However, the spleen rate is not an entirely malaria-specific metric 
and has largely been replaced by more specific methods, e.g. evaluation of parasite 
prevalence, which has become the most frequently collected transmission metric (120).  
In areas where malaria is endemic, both the spleen rate and parasite prevalence  
have traditionally been used to categorise the intensity of transmission into four endemicity-
levels:  holoendemic >75%, hyperendemic 51–75%, mesoendemic 11–50%, and  
hypoendemic <10% (121). 
Although useful and well established, the evaluation of parasite prevalence has several 
limitations with regards to quantifying the intensity of transmission. The prevalence of 
infection tends to saturate when transmission intensity is high, partly due to acquired 
immunity within the population and heterogeneous biting by the mosquito vectors (122). In 
high transmission settings parasite prevalence therefore underestimates the intensity of 
transmission and has limited possibility to detect transmission changes (117). Parasite 
densities also vary substantially during the course of an infection (e.g. due to sequestration, 
the age of the infection, the individual level of acquired immunity) and may fluctuate 
between undetectable and detectable levels. Samples collected at a single time-point may 
therefore underestimate the level of transmission in the population (123,124). Furthermore, 
microscopy, which has traditionally been the standard method to evaluate parasite prevalence, 
lacks the sensitivity to detect very low-density infections. These so called sub-microscopic 
infections can be detected with more sensitive molecular methods, e.g. polymerase chain 
reaction (PCR), and such methods may be a valuable alternative for evaluation of parasite 
prevalence in particular in low transmission settings (125). However, when transmission is 
low and the true prevalence of infection is less than approximately five per cent, the utility of 
prevalence surveys is limited due to the difficulty in sampling sufficient numbers of parasite 
positive individuals to obtain reliable estimates of the parasite prevalence (123,125).  
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Estimates of malaria disease incidence provide a more direct indicator of transmission burden 
and are more sensitive than parasite prevalence when transmission is low (126). Such 
estimates are often also easier to obtain as they can be based on passively collected data from 
hospital clinical records reported through healthcare surveillance systems. However, data on 
clinical incidence are often unreliable because there tends to be a substantial overdiagnosis of 
clinical cases at the health facilities while cases occurring in the community are missed due to 
low care-seeking rates. Furthermore, in many malaria endemic countries there is a large 
discrepancy between the number of cases diagnosed at health facilities and the number of 
cases actually reported to surveillance system (1,4,5,43). 
The collection of entomological parameters such as the EIR, i.e. the average number of 
infectious mosquito bites received per individual and year, provides a way to directly 
measure the intensity of transmission. The EIR has therefore often been considered the gold-
standard method for estimating malaria transmission intensity (119). However, data on EIR, 
traditionally based on human landing catches, are notoriously difficult, expensive, and labour 
intensive to collect (127). Furthermore they are often imprecise, particularly in low 
transmission settings, because of heterogeneity in both malaria transmission and vector 
distribution (128–130). 
For many infectious diseases, the most direct measure of transmission intensity is often the 
force of infection, i.e. the rate at which susceptible individuals become infected (131). 
However, for a disease such as malaria where there is a long latency period between infection 
and onset of symptoms and where both asymptomatic and multiclonal infections are 
common, estimating the force of infection is difficult (132). Obtaining reliable estimates of 
the force of infection of P. falciparum requires both high-frequency active longitudinal 
sampling and the use of sensitive molecular techniques that can distinguish super-infections 
from old infections (131,133). Even if this can be achieved, the highest intensity that can be 
accurately estimated will be determined by how often the samples are collected. 
As for the other metrics discussed above, estimates of the force of infection will also be 
affected by the sensitivity of the parasite detection method and by fluctuations in parasite 
densities during the course of infection (117).  
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1.5 SEROLOGY AS AN EPIDEMIOLOGICAL TOOL 
As previously described antibodies are key components of the effective antimalarial immune 
response. However, given that antibodies are maintained beyond the length of an actual 
infection, they may serve as a serological footprint of prior infections (134). Serology has 
become an increasingly important tool for the surveillance of a wide range of infectious 
diseases in both humans and animals and can provide alternative means of estimating the 
force of infection (135). In the context of malaria, not only the parasite proteins, but also 
proteins in mosquito saliva that are injected into the skin during mosquito blood-feeding 
induce strong antibody responses (136–138). Parasite and mosquito serology can therefore be 
used to evaluate malaria and vector exposure, respectively.  
A serological sample taken at a certain point in time provides information on whether the 
individual has been exposed prior to that time-point. Antibodies in plasma are generally 
measured in a semi-quantitative fashion. However, in seroepidemiological studies, the 
quantitative measurement is often dichotomised by comparing it to a predetermined threshold 
in order to define whether the individual has been previously exposed or not (i.e. is 
seropositive or seronegative) (135). If a disease is endemic, knowledge about the rate at 
which individuals in a cohort pass from seronegative to seropositive, i.e. the rate of 
seroconversion (SCR), provides information on the force of infection. In theory this could be 
accurately estimated from a longitudinal study in which a population is followed from birth 
and the rate at which people get infected and thus seroconvert is identified (139). 
For example, let us consider that a cohort of malaria naïve children who live in an area where 
the disease is endemic (technically at endemic equilibrium) is sampled at birth for the 
measurement of malaria specific antibodies. For the sake of simplicity we assume that they 
have no maternal antibodies and that they are therefore all seronegative. During their first 
year of life a proportion of the children in the cohort will have malaria. If we conduct a 
serological follow-up study in the same children after a year, we will find that a proportion of 
the children are now seropositive as a reflection of having been infected during their first year 
of life. If we conduct a new follow-up study after another year, an additional number of 
children will have acquired the infection and therefore seroconverted. If the duration of 
seropositivity is sufficiently long, the proportion of seropositive children will increase with 
time as a consequence of exposure. 
Longitudinal serological cohort studies are often difficult or even impossible to conduct due 
to time and resource constraints, however cross-sectional serological population surveys may 
provide much similar information and are therefore commonly used as an alternative way to 
study the epidemiology infectious diseases (135,140,141). The conceptual similiarities 
between a longitudinal serological study following a cohort from birth and cross-sectional 
serological population survey are illustrated in Figure 4.  
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Figure	4.	Schematic	illustration	of	conceptual	differences	and	similarities	in	data	from	longitudinal	serological	
cohort	studies	and	cross-sectional	serological	population	surveys.	(Adapted	from	Hens	et	al.	2012	(135),	
reproduced	with	permission	from	Springer	Science	+	Business	Media)	
	
As illustrated in Figure 4, a population can be thought of as consisting of multiple cohorts 
(C1-C4) of individuals born at different points in time. As time passes the individuals within 
each of these cohorts will become older, as illustrated by the solid diagonal lines. In a 
longitudinal serological study we would follow one of the cohorts, e.g C1, from birth (i.e. 
along the diagonal line) and examine the rate at which individuals seroconvert as a 
consequence of exposure. However, a cross-sectional sample of the population at time t 
(indicated by the vertical dashed blue line) can be considered to capture all of the cohorts (C1-
C4) at a certain point in time, and thereby the individuals within each cohort at a certain age a 
(indicated by the horizontal dotted green line). The proportion of seropositive individuals of 
each age (a1-a4) at time t could thus be considered to represent the cumulative exposure 
within each of the cohorts (C1-C4) that they represent. The rate of increase in seroprevalence 
with age will provide information of how fast individuals in the population seroconvert and 
can therefore be used as a marker of the force of infection.  
Age
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1.5.1 Estimating seroconversion rates from cross-sectional data 
A common pattern in the age-specific prevalence of antibodies to malaria in a population 
living in areas where the disease is endemic is illustrated in Figure 5. 
 
 
Figure	5.	Typical	age	pattern	in	prevalence	of	malaria	specific	antibodies	in	a	population	living	in	an	endemic	
area.	Data	on	seropositivity	to	MSP-1	or	AMA-1	from	17,503	individuals	participating	in	baseline	surveys	of	the	
REDHOT	cluster	randomised	trial	(Bousema	et	al.	2016	(142)).	Each	dot	represents	the	seroprevelence	within	a	
one-year	age	stratum.	The	size	of	the	dots	represents	the	number	of	individuals	in	each	age	stratum.	Data	is	
publicly	available	through	the	Dryad	data	repository	https://doi.org/10.5061/dryad.nr8d8.	
	
As exemplified in Figure 5, seroprevalence often increases with age until reaching a plateau 
where it saturates in the population. This saturation implies one or more of the following: i) 
not all individuals in the population become exposed, ii) for a given antigen, not all 
individuals will seroconvert upon exposure, or iii) antibody responses once acquired can also 
be lost (143). The loss of antibodies leading to a transition from seropositive to seronegative 
is referred to as seroreversion. The increase in seroprevalence in the population with age can, 
as previously described, be described using a reversible catalytic seroconversion model 
(serocatalytic model) (139,141,144–146).  
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If seronegative individuals become seropositive at a rate λ(t), and if seropositive individuals 
revert to seronegative at a rate ρ, the proportion of seropositive individuals in a cohort P is 
described by the following differential equation:  
 	dPdt = λ(t)(1−P)− ρP     (1) 
 
Assuming constant intensity in transmission this equation can be solved to give estimates of 
the proportion of individuals of age a that are seropositive: 
   (2) 
where P(a) is the proportion of individuals of age that are seropositive, λ is the rate of 
seroconversion, ρ the seroreversion rate and a the age of the individual at the time when the 
sample was collected. The model parameters (λ and ρ) are estimated by fitting the model to 
cross-sectional data on age-specific antibody prevalence. By allowing the seroconversion rate 
to vary in the population over time, the model can be extended to evaluate temporal changes 
in the force of infection (143,147,148). 
The seroconversion rate provides a robust surrogate marker of the force of infection of 
malaria and has been previously validated across a wide range of transmission settings (146). 
Furthermore, seroconversion rates for a number of P. falciparum pre-erythrocytic (e.g. CSP 
and PfCelTOS) (149) and blood stage antigens (e.g. MSP-1, MSP-2, and AMA-1) 
(146,150,151) have been estimated to examine the magnitude and temporal trends in 
transmission intensity in different geographical areas (152–157). Besides malaria, catalytic 
models based on age-specific seroprevalence have been applied to estimate the force of 
infection of a number of parasitic infections (e.g. toxoplasmosis (158), and onchocerciasis 
(159)), as well as both viral infections (e.g. dengue (160,161), hepatitis A and B (162,163), 
rubella (164), measles (165), respiratory syncytial virus (166)) and bacterial infections (e.g. 
Chlamydia trachomatis (167)). 
As described above, antibody responses are generally measured in a semi-quantitative 
fashion. However, the use of serocatalytic models to estimate the seroconversion rates from 
cross-sectional data requires the quantitative antibody measurements to be dichotomised into 
simply seropositive or seronegative. This process of dichotomisation leads to a substantial 
loss of information contained in the quantitative antibody measurement (168). Furthermore 
defining the threshold of seropositivity is complicated and an inappropriate threshold may 
lead to spurious estimates of the seroconversion rate (151,169,170). It is therefore likely that 
a method that makes use of the information provided by the quantitative antibody 
measurements, thereby avoiding dichotomisation, could improve the precision in 
transmission estimates.  
	P(a)= λλ + ρ (1−e(λ−ρ )a)
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1.5.2 Longitudinal data on individual antibody dynamics 
In an individual plasma sample collected in a cross-sectional survey the level of pathogen-
specific antibody can often give some indication of how recently the individual was infected. 
Higher levels tend to indicate a more recent exposure but can also reflect a greater cumulative 
exposure (171,172). However, there are distinct temporal dynamics in the magnitude of 
specific antibody responses after infection (68). If these temporal dynamics are sufficiently 
predictable both within and between individuals, the dynamics of the response can be 
exploited to estimate when an individual was last infected with a specific pathogen. Given 
that the dynamics can be accurately described, cross-sectional data on antibody responses can 
theoretically provide a direct measurement of the force of infection (131). In such cases, a 
reliable model of the dynamics in antibodies after infection must first be created. Given a 
measured antibody level, this model can then be used to back-calculate the time since 
infection, which in turn can be used for incidence estimation (131). 
For many pathogens, including P. falciparum, however, the lack of accurate quantitative 
estimates of how the magnitude of the antigen-specific individual-level antibody response 
changes over time after infection is a common and important limitation for developing 
models that can reliably predict the time since infection (131). Such quantitative estimates are 
preferably obtained through the longitudinal study of the dynamics of antibodies after 
infection. However, it is difficult to obtain reliable quantitative estimates for P. falciparum by 
studying individuals living in areas where malaria is endemic. Studies are hampered both by 
the latency between infection and symptom onset and the overall high frequency of low-
density asymptomatic infections which make it difficult to determine when an infection 
actually started (173). Furthermore, because of a continuous risk of re-infection during 
follow-up that can lead to antibody boosting, the decay in antibody levels is difficult to 
accurately characterise (68). For P. falciparum, The situation is further complicated by the 
fact that individuals may harbour infections with multiple parasite clones by which they have 
been infected at different points in time (174,175). 
Experimental challenge studies of controlled human malaria infection (CHMI), in which the 
exact time-point of infection is known, could be used to partially address these issues (35). 
However, participants in CHMI trials are typically treated at microscopic patency of blood-
stage infection, which in many cases occurs before the onset of symptoms (176,177). The 
dynamics of the antibody response following CHMI may therefore not reflect the dynamics 
of the response following a symptomatic natural blood-stage infection in which parasitaemia 
is higher and the inflammatory response more pronounced (35). 
However, if studying individual-level dynamics of antibody responses in travellers returning 
with malaria to a malaria free country after short-term travel it would be possible to 
significantly narrow down the time-point when infection occurred. A follow-up of malaria 
infected travellers in a malaria free country would also make it possible to study the decline 
in antibody levels in complete absence of re-exposure, allowing for a detailed characterisation 
of the dynamics of the response.  
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If such a study includes individuals with varying levels of prior malaria exposure it would 
also be possible to identify whether the response to some antigens provides information on 
recent exposure while the response to others reflects the cumulative magnitude of prior 
exposure. 
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2 AIM 
The overall aim was to investigate how malaria exposure affects the acquisition and 
maintenance of the antimalarial antibody response with the goal to improve our 
understanding of antimalarial immunity and develop new methods for monitoring malaria 
transmission. 
Our specific aims were to: 
I. Evaluate the temporal trends in malaria transmission over 25 years in a Tanzanian 
village using estimates of parasite prevalence obtained with different methods and 
to assess the impact of the presence of a research team. 
II. Evaluate temporal trends in malaria transmission using serology and develop new 
mathematical models that can improve serological surveillance of transmission 
intensity. 
III. Characterise the dynamics and longevity of antibodies and antibody secreting 
cells following a single malaria infection. 
IV. Identify serological signatures of recent and cumulative malaria exposure. 
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3 MATERIALS AND METHODS 
Brief overviews of the most important materials and methods are described in this section. 
More detailed descriptions are presented within the corresponding papers or manuscripts. 
3.1 STUDY POPULATIONS 
3.1.1 Nyamisati Tanzania (Study I and II) 
Studies I and II were conducted within a longitudinal project on the epidemiology of malaria 
in Nyamisati, a rural fishing village situated in the Rufiji river delta in coastal Tanzania, 
approximately 150 km south of Dar es Salaam (S 7°47’43’’, E 39°16’31’’). Malaria 
transmission in the area is perennial with seasonal increases following longer periods of rain 
occurring twice yearly. The predominating vectors in the area belong to the Anopheles 
gambiae complex and are An. gambiae sensu strictu, An. arabiensis, and An. merus 
(178,179). The research project was established in 1985 and a research team, who lived in the 
village, maintained a primary health care unit and monitored malaria cases through a passive 
case detection system operational from 1986-88 and 1993-1999. Furthermore, repeated cross-
sectional surveys, in which all villagers were invited to participate, were conducted in 1986-
1988, 1993-1999, and in 2010. The surveys consisted of a clinical examination of health 
status including evaluation of spleen size according to Hackett’s score (118), measurement of 
haemoglobin levels, collection of blood slides as well as of venous blood samples stored 
separated as packed cells and plasma. Insecticide treated nets (ITNs) were distributed to 
pregnant women and mothers with small children after the survey in 1993 and to all survey 
participants after the survey in 1999. Long-lasting insecticidal nets were distributed to all 
survey participants after the survey in 2010. Other vector control measures such as IRS or 
larviciding have not been deployed in the area. Study I includes all available survey data on 
health status, spleen size, haemoglobin levels, and parasite positivity by microscopy as well 
as data on malaria incidence recorded through the passive case surveillance system 1986-
1988 and 1993-1999. Available samples collected in surveys conducted in 1994-1995, 1999, 
and 2010 were selected for analysis by parasite-specific PCR. For study II, plasma samples 
collected from children 1-16 years old who participated in the cross-sectional surveys 
conducted in 1999 and 2010 were selected for the analysis of antibody responses. 
3.1.2 Swedish travellers cohort (Study III and IV) 
Studies III and IV were conducted within a prospectively followed cohort of travellers. 
Sixty-five adult travellers diagnosed with Plasmodium falciparum malaria at Karolinska 
University hospital were enrolled in the study upon hospitalisation. Venous blood samples 
were collected at enrollment and study participants were invited to provide follow-up samples 
after ten days, and one, three, six and twelve months. A questionnaire detailing country of 
origin, previous countries of residence, medical and travel history as well as prior malaria 
exposure was administered to all study participants at enrollment and at the end of follow-up. 
Study participants differed in terms of their prior malaria exposure.  
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Twenty-one individuals were born in a malaria-free country and reported no prior malaria 
exposure, three individuals who were born in a malaria-free country reported, or had a 
confirmed, single prior episode of clinical P. falciparum malaria, and forty-one individuals 
who were born, or had lived a substantial period of time, in a malaria endemic country, 
reported multiple prior clinical malaria episodes. Study III was restricted to include subjects 
with either no prior or multiple prior episodes of clinical malaria while study IV included all 
subjects in the cohort. 
3.1.3 Negative controls 
For studies II and III, plasma samples from 20 Swedish donors who had never travelled to a 
malaria endemic area were analysed as negative controls. For study IV, a different set of 
plasma samples from 42 malaria naïve European donors were analysed as negative controls. 
3.2 ETHICAL CONSIDERATIONS 
Studies I and II were granted ethical approval by the Nyamisati village board, the Ethical 
Review board of the National Institute of Medical Research in Tanzania, the Regional Ethical 
Committee at Karolinska Institutet, and the Regional Ethical Review Board in Stockholm. 
Studies III and IV were approved by the Regional Ethical Review Board in Stockholm. 
Informed consent was obtained from all study participant or, when applicable, the study 
participant and/or their guardians. 
3.3 PARASITE DETECTION 
3.3.1 Microscopy (Study I) 
Examination of Giemsa-stained thick and thin films was performed using light microscopy. 
Parasite densities were estimated per microlitre of blood and were enumerated against the 
number of leukocytes by assuming there are 8000 leukocytes per microlitre. Blood films were 
considered negative if no parasites were detected following examination of 100 fields of the 
thick film. 
3.3.2 Polymerase chain reaction (PCR) (Study I) 
Detection of P. falciparum parasites by PCR was performed in study I to assess the 
prevalence of infection. Briefly, DNA was extracted from packed cells in EDTA using 
Qiagen blood mini kit (Qiagen, Germantown, MD, USA), phenol-chloroform extraction, or 
using an automated Qiagen BioRobot® M48 (Qiagen). A plasmodium species-specific real-
time PCR assay targeting the multicopy 18S rRNA gene was performed using an ABI 
TaqMan 7500 instrument (Applied Biosystems, Foster City, CA, USA) (180). In addition, a 
nested PCR assay targeting the two allelic types of the polymorphic single copy msp2 gene 
was performed using fluorescently labelled primers and fragment sizing by capillary 
electrophoresis (181,182). 
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3.4 ANTIBODY ASSAYS 
3.4.1 Anopheles gambiae salivary gland protein 6 ELISA (Study II) 
An enzyme-linked immunosorbent assay (ELISA) protocol was used to evaluate the  
antibody response towards the recombinant Anopheles gambiae salivary gland protein 6 
(gSG6) (137,183). Microtitre plates (Costar® Corning, Tewksbury, MA, USA) were coated 
overnight at 4°C with 25 µl per well of recombinant gSG6, at 5 µg/ml in sodium-carbonate 
buffer. After washing and blocking, 25 µl of test plasma at 1:100 dilution were added and 
incubated at 37°C for 1 hour. After washing, IgG was detected using 25 µl per well of 
alkaline-phosphatase conjugated goat anti-human IgG (Mabtech, Nacka, Sweden). The assay 
was developed with p-nitrophenyl phosphate disodium substrate (Sigma-Aldrich, St. Louis, 
MO, USA), and after stopping the reaction with 1M hydrochloric acid, optical densities (OD) 
were read at 405 nm using a VmaxTMKinetic microplate reader (Molecular Devices, 
Sunnyvale, CA, USA). 
3.4.2 Schizont extract ELISA (Study III) 
An ELISA was used to quantify total IgG levels to schizont extract according to a previously 
described protocol (184). Each well of microtitre plates were coated overnight at 4°C with 
100 µl of P. falciparum schizont extract (3D7 clone) at 2 µg/ml. After blocking and washing, 
plates were incubated with 100 µl of test plasma at 1:1000 dilution overnight at 4°C. Bound 
IgG was detected by horseradish-peroxidase conjugated rabbit anti-human IgG (Dako, 
Glostrup, Denmark). Plates were developed with o-phenylenediamine dihydrochloride and 
the reaction stopped with 2M H2SO4. ODs were read at 492 nm using a VmaxTMKinetic 
microplate reader (Molecular Devices). 
3.4.3 Bead-based immunoassays (Study II and III) 
In studies II and III, a multiplex bead-based immunoassay was used for the simultaneous 
quantification of IgG antibody responses to multiple recombinant P. falciparum antigens as 
previously described (185). Briefly, each antigen was covalently coupled to a spectrally 
unique set of carboxylated paramagnetic beads (Bio-Rad Laboratories, Hercules, CA, USA). 
Antigen coupled beads were mixed and incubated with test plasma at room temperature. 
Bound antigen-specific antibodies were detected using R-phycoerythrin conjugated F(ab’)2 
goat anti-human IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) 
and the assay readouts were obtained using a Bio-Plex 200 instrument (Bio-Rad 
Laboratories). For study II, the assay antigens included the 19 kDa fragment of merozoite 
surface protein 1 (MSP-119) (186), and two allelic variants of each of MSP-2 (187), MSP-3 
(188), and apical membrane antigen 1 (AMA-1) (189). For study III the assay was expanded 
to also include the RH5 antigen (190,191) and was repeated for quantification of the response 
of each of the four IgG subclasses (IgG1-4) in addition to total IgG, as previously described 
(192). Furthermore, for study III, an additional monoplex bead-based immunoassay was used 
for detection and quantification of total IgG antibodies to tetanus toxoid (TTd) according to a 
previously described protocol (193). 
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3.4.4 Antibody microarray (Study IV) 
The KILchip v1.0 protein microarray (Kamuyu et al., Manuscript under review) was used in 
study IV to simultaneously screen plasma samples for antibody reactivity towards 111 P. 
falciparum antigens corresponding to 88 unique proteins. The selection, expression and 
purification of antigens have been previously described (48,51,187,188,194–198). Out of the 
111 antigens, 82 were full-length ectodomains or, if multimembrane proteins, corresponded 
to the largest predicted extracellular loop while 29 were protein fragments of 8 unique 
proteins (i.e. MSP-1, MSP-2, MSP-3, MSPDBL1, MSPDBL2, PfSEA-1, PF3D7_06293500 
and Surfin 4.2) (187,188,194–196). Out of the 29 fragments, 16 were derived from the 3D7 
sequence while 13 were derived from non-3D7 sequences (i.e. cho150/9, Dd2, K1, MAD20, 
PaloAlto, RO33, and Wellcome). Plasma samples were assayed in 1:400 dilution and bound 
antibody was detected using AlexaFluor647 conjugated donkey anti-human IgG. The 
processed microarray slides were read at 635 nm using a GenePix® 4000B scanner 
(Molecular Devices) and results obtained using the GenePix® Pro 7 software (Molecular 
Devices). In order to account for day-to-day and slide-to-slide variation in assay signal 
intensity, normalisation was performed using robust linear models as previously described by 
Sboner et al. (199). 
3.4.5 Defining thresholds of seropositivity 
For all immunoassays, thresholds of seropositivity were defined for each antigen as the  
mean antigen-specific reactivity of malaria unexposed negative controls + 3 standard 
deviations (SD).  
3.4.6 Converting assay signal intensity to relative antibody concentration 
In all bead-based immunoassays and ELISAs, a serially diluted standard calibrator of either 
purified IgG from malaria immune donors (multiplex bead-based assay, schizont extract 
ELISA), recombinant human IgG (gSG6 ELISA), or pooled plasma from highly tetanus 
immune donors (tetanus toxoid assay) was assayed on each plate on each day of experiment 
to provide a standard calibrator curve used to control for day-to-day and plate-to-plate assay 
variation. Each assay OD or MFI was converted to a relative concentration in arbitrary units 
by interpolation from the corresponding standard calibrator curve using a five-parameter 
sigmoidal curve fitting.  
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3.5 STATISTICAL ANALYSIS AND MATHEMATICAL MODELLING 
Statistical analysis and mathematical modelling were performed using Stata v12 to v14 (Stata 
Corp., College Station, TX, USA) and R v3.2.2 to v3.4.4 (R Core Team, Vienna, Austria). 
3.5.1 Logistic regression models (Study I) 
In study I, multivariable generalised estimating equation logistic regression models were used 
to evaluate the temporal trends in parasite prevalence, determined by microscopy and each of 
the two PCR methods, and anaemia prevalence while adjusting for known and potential 
confounders, e.g. age and sex. Age was treated as a categorical variable with 5 categories. An 
interaction effect between age and survey year was included in all models. 
3.5.2 Serocatalytic models for antibody prevalence (Study II) 
To evaluate temporal trends in malaria transmission intensity using serology, a previously 
described reversible catalytic seroconversion (serocatalytic) model was used to estimate the 
annual rate of seroconversion (SCR) from cross-sectional data on age-specific seroprevalence 
(146). The serocatalytic model was fitted separately to seroprevalence data for each antigen 
but jointly to data from both cross-sectional surveys included in study II. Three different 
models, representing three possible malaria transmission intensity patterns over time, i.e. 
constant transmission (M1), single sharp stepwise reduction (M2), or continuous linear 
reduction (M3) in transmission intensity, were evaluated. For each antigen, the best 
performing model, and thus most likely transmission pattern, was identified in terms of the 
lowest Akaike Information Criterion (AIC) value (200). 
3.5.3 Antibody acquisition models for antibody levels (Study II) 
We developed novel models for estimation of transmission intensity, referred to as antibody 
acquisition models, based on cross-sectional data on age-specific antibody levels. The 
antibody acquisition models, which incorporate insights from longitudinal antibody 
dynamics, assume that antibody levels increase as a function of age and therefore that the rate 
at which they are acquired can be used as an alternative marker of transmission intensity 
(Figure 6) (68,141). 
If an individual’s antibody level is boosted at a rate α and decays at a rate r, the antibody 
levels can be described by the following differential equation: 
 
	
dA
dt
=α t( )− rA  (3) 
By allowing α to vary over time we evaluate different scenarios for a change in transmission 
intensity. The models were fitted to the data analysed in study II in the same way as 
described for the serocatalytic models. The same three alternative transmission patterns were 
evaluated and the most likely pattern was identified based on the model AICs. 
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Figure	6.	Schematic	representation	of	how	the	antibody	acquisition	model	incorporates	insights	from	
longitudinal	antibody	dynamics.	The	dashed	line	provides	an	illustration	of	how	a	naïve	individual	is	assumed	
to	acquire	an	antibody	response	with	time.	Each	new	infection	is	assumed	to	cause	a	consequent	increase	in	
antibody	levels	until	reaching	a	plateau	where	no	further	increase	is	possible	(68,141).	The	solid	green	line	is	
the	corresponding	average	increase	in	the	population	antibody	levels	with	time.	In	the	context	of	cross-
sectional	data,	the	analogous	scenario	can	be	represented	by	the	level	of	antibodies	at	each	age.	We	assume	
that	the	average	annual	rate	of	increase	in	antibody	levels	with	age	can	be	used	as	a	marker	of	transmission	
intensity.	 	
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3.5.4 Antibody dynamics model (Study III) 
In study III, the longitudinal data on antibody responses was analysed using a mathematical 
model that captures the dynamics of the antibody response while simultaneously allowing 
estimation of the longevity of both antibodies and antibody secreting cells. The model is an 
extension of the antibody dynamic model, previously described by White et al., that 
incorporates the possibility to account for differences in the individual level of prior exposure 
(68). 
The rise and fall in antibody levels after infection at time τ0 can be represented by the 
following equation: 
 
 
 	A t( ) = A0e−rl (t−τ0 ) + 1− ρ( )e−rs (t−τ0 ) −e−ra(t−τ0 )ra − rs + e−rl (t−τ0 ) −e−ra(t−τ0 )ra − rl⎛⎝⎜ ⎞⎠⎟  (4) 
 
 
As further illustrated in Figure 7, the model assumes that in previously naïve individuals, 
infection at time τ0, leads to the proliferation and differentiation of B-cells generating an 
amount β of ASCs that secrete IgG. A proportion of the ASCs (ρ) are long-lived and decay at 
rate rl while a proportion (1-ρ) are short-lived and decay at rate rs. causing a biphasic decay in 
antibody levels. All ASCs produce antibodies that decay at rate ra. Individuals who have had 
prior P. falciparum infections may maintain a level of pre-existing antibodies (A0), generated 
during previous infections, that decay at rate ra and are maintained by old long-lived ASCs, 
which decay at rate rl. Naïve individuals, who suffer a primary P. falciparum infection, are 
assumed to have no pre-existing antibodies or ASCs at the onset of infection (A0 = 0). The 
above model is valid for all t greater than τ0. 
The model accounts for exposure related differences in the dynamics of the response by 
allowing for differences in the magnitude of antibody increase (i.e. boosting) upon infection 
and in the proportion of long-lived ASCs that are generated and maintained.  
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Figure	7.	Schematic	representation	of	the	antibody	dynamics	model.	The	top	row	represents	how	the	model	
captures	the	underlying	immunological	processes	depending	on	prior	exposure	and	the	bottom	row	depicts	the	
change	in	antibody	levels	over	time.	
3.5.5 Decay in antibody reactivity (Study IV) 
In study IV, the antigen-specific rate of decay in antibody reactivity was estimated using 
mixed effects models as previously described (78,201). Antibody levels were assumed to 
decay exponentially over time, corresponding to a linear decay in log antibody levels. Models 
were fitted to the log-transformed MFI data that had been curated to include only data from 
the decay phase of the response towards each antigen. The rate of decay was expressed as the 
half-life of the antibody response (78,201). 
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3.5.6 Antibody responses predictive of recent exposure (Study IV) 
In study IV we used binary classification analysis to evaluate if the antibody response to a P. 
falciparum antigen was predictive of whether a sample was collected from a recently infected 
individual. A recent infection was defined as an infection having occurred within 90 days of 
sample collection. Univariable logistic regression models were fitted to data for each of the 
antigens individually. Receiver operating characteristic (ROC) analysis was used to evaluate 
the classification performance of each model and a cross-validation was performed for each 
classifier using repeated random sub-sampling in order to evaluate the classifier performance 
outside of its training sample (202). To evaluate if classification could be improved by 
incorporating data on the response to multiple antigens, we first performed a feature selection 
with the Boruta algorithm, a wrapper method built around a random forest classification 
algorithm, as previously described (203). The Boruta algorithm was fitted jointly to antibody 
data for all immunogenic antigens and antibody responses identified as contributing 
significant information to classification of recent exposure were selected for further 
evaluation. Multivariable logistic regression models were fitted to all possible two- to five-
way combinations of antibody responses to these selected antigens. In order to evaluate 
whether a combination of responses could improve performance of classification of recent 
infection we examined the classifier cross-validated area under the ROC curve (AUC). 
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4 RESULTS 
4.1 STUDY I 
In order to characterise the temporal trends in malaria transmission in Nyamisati, Tanzania, 
we analysed data on spleen rate, parasite prevalence, and haemoglobin levels collected in 
repeated cross-sectional surveys conducted between 1985 and 2010. Parasite prevalence was 
evaluated using microscopic examination of blood slides as well as two different PCR 
methods. During the 1980’s, efforts to limit malaria transmission consisted of providing 
prompt diagnosis and antimalarial treatment. Insecticide treated nets (ITNs) were first 
introduced after the cross-sectional survey in 1993, when the research team distributed 300 
nets to pregnant women and families with small children. An additional round of 900 ITNs 
were distributed after the survey in 1999. Assuming one net on average provides protection 
for 1.8 individuals, these interventions were estimated to have achieved a bed net coverage of 
approximately 45% in 1993 and 100% in 1999 (204). 
Between 1985 and 2010, we observed a substantial decline in all evaluated malaria 
transmission metrics. The reduction started before the introduction of ITNs and a decline in 
the malaria burden was first observable in the spleen rate, in which a decline was discernible 
already during the 1980’s. This was later followed by a reduction in parasite prevalence as 
well as a concurrent decline in the prevalence of both severe and moderate anaemia. The 
overall parasite prevalence by microscopy, which was 70% in 1985 declined, gradually 
during the 1990’s to 39% in 1994 and 27% in 1999, reaching an estimated 5% in 2010 
(Figure 8). 
 
 
Figure	8.	Temporal	trends	in	parasite	prevalence.	Bars	denote	the	all-age	prevalence	for	each	method	and	the	
error	bars	the	95%	CI.	*	indicates	that	data	has	been	estimated	from	corresponding	microscopy	or	PCR	data	
using	the	prevalence	estimation	tool	developed	by	Okell	et	al.	(125).	ITNs	and	LLINs	indicate	the	distribution	of	
insecticide	treated	nets	and	long-lasting	insecticidal	nets,	respectively,	after	the	survey.	 	
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The observed PCR prevalence, which was consistently higher than corresponding estimates 
based on microscopy, declined substantially between 1994 and 2010 from 69.4% to 17.8% 
and 59% to 16% when evaluated by real-time PCR and msp2-PCR, respectively. The 
magnitude of the estimated annual reduction in PCR prevalence was age-specific and was 
greatest among children 5-8 years of age (real-time PCR, Odds ratio [OR]: 0.79, 95% CI: 
0.76-0.83; msp2-PCR, OR: 0.80, 95% CI: 0.76-.85) and 9-12 years of age (real-time PCR, 
OR: 0.79, 95% CI: 0.76-0.83; msp2-PCR, OR: 0.82, 95% CI: 0.79-0.86). Over time this lead 
to a shift in the age-prevalence pattern and at the end of the study period the highest 
prevalence was observed among 13-16 years old children. Furthermore, there was a 
significant reduction in the prevalence of any level anaemia from 1994 to 2010 (OR: 0.32, 
95% CI: 0.24-0.41).  
  29 
4.2 STUDY II 
In study II, we developed new antibody acquisition models for serological surveillance based 
on cross-sectional data on antibody levels with the aim to improve serological estimates of 
malaria transmission intensity. The new models make use of the data on individual antibody 
levels by assuming that antibody levels increase as a function of age. Further they assume 
that the rate at which antibody levels are boosted by exposure can be used as an alternative 
marker of transmission intensity. To evaluate the performance of the antibody acquisition 
models, we compared them to the previously validated serocatalytic models based on 
antibody prevalence (146) and applied both approaches to further examine the temporal 
transmission patterns in Nyamisati described in study I. 
We analysed data on antibody responses to P. falciparum and An. gambiae antigens 
measured in children 1-16 years old who participated in the cross-sectional surveys 
conducted in Nyamisati village in 1999 (n = 313) and 2010 (n = 355). For each individual 
antigen, i.e. MSP-119, two allelic variants of each of MSP-2, MSP-3 and AMA-1, and gSG6, 
serocatalytic and antibody acquisition models were fitted jointly to data from both cross-
sectional surveys. Based on the known reduction in parasite prevalence over time (study I), 
we evaluated a set of three models for each modelling approach, each assuming a different 
temporal pattern in transmission intensity, i.e. no change (M1), single sharp stepwise 
reduction (M2), or continuous linear reduction (M3). 
We observed a significant reduction in both prevalence (χ2-test: all p<0.001) and levels 
(Mann Whitney-U test: all p<0.001) of antibodies to all P. falciparum antigens and the gSG6 
from 1999 to 2010. Seroprevalence and levels of antibodies increased with age at both 
surveys except for MSP-119, and MSP-3 antigens, for which there was no age-trend in 
antibody levels at the 2010 survey, and for gSG6, for which neither prevalence nor levels 
displayed an age-trend at either survey. The serocatalytic models assuming constant 
transmission (M1) provided poor fit to data for all evaluated antibody responses but a 
substantial reduction in transmission intensity was identified by models assuming changes in 
the intensity of transmission (M2 and M3). For several antigens, the serocatalytic models 
assuming a stepwise reduction (M2) provided estimates of a 61 to 79% reduction in 
transmission intensity with a time-point of change between 1997 and 2000 while models 
assuming a linear decline in transmission intensity (M3) estimated a reduction  
of 64 to 95%. However, the models exhibited a considerable degree of uncertainty in 
parameter estimates for which confidence intervals were wide and for a majority of antigens 
the serocatalytic models were unable to determine whether a stepwise (M2) or a linear 
reduction (M3) had been most likely (comparing M2 to M3: ΔAIC <2). 
The antibody acquisition models overall provided a better fit to data, more consistent 
estimates across antigens, as well as greater precision in parameter estimates. A model 
assuming a stepwise reduction (M2) in transmission intensity provided superior fit to data 
(i.e. with smaller AIC values) than a model assuming a linear reduction (M3) in transmission 
intensity for all P. falciparum antigens (Figure 9, Table 1).
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Depending on antigen, the stepwise decrease model estimated a 72 to 92% reduction in 
transmission intensity and for a majority of antigens the reduction, corresponding to the 
largest single reduction event, was estimated to have occurred between 1997 and 2000 
(Figure 10, Table 1). 
 
 
Figure	10.	Estimated	changes	in	transmission.	Model	estimates	from	antibody	acquisition	models	assuming	a	
stepwise	reduction	in	transmission	intensity.	Lines	represent	the	estimated	magnitude	and	time-point	of	
change	from	the	model	fitted	to	each	of	the	antigens.	
	
Furthermore, a complementary sensitivity analysis based on both simulated data (simulated 
using the antibody acquisition model) and the data for AMA-1_3D7, demonstrated that the 
antibody acquisition models are more robust than serocatalytic models when the sample size 
is small. Reducing the samples size to 50 or 100 samples per cross-section decreased both 
accuracy and precision of serocatalytic model estimates whereas it only slightly affected the 
precision of the antibody acquisition model.  
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4.3 STUDY III 
In study III, we investigated the dynamics of the total IgG and IgG subclass response to P. 
falciparum schizont extract and recombinant vaccine candidate antigens (MSP-119, MSP-2, 
MSP-3, AMA-1, and RH5) in travellers followed prospectively, and in complete absence of 
re-exposure, after treatment of a clinical malaria episode. In total, 61 adult travellers, 41 
previously malaria exposed and 20 previously malaria naïve, were enrolled in the study upon 
diagnosis and followed with repeated blood sampling during the subsequent year. We used 
mathematical models to examine the exposure dependent dynamics of the antibody response 
and to estimate the decay rates of antibodies and short- and long-lived ASCs, as well as the 
relative contribution from short- and long-lived ASCs to the overall response. To provide a 
validation of our estimates we also examined the dynamics of the antibody response to the 
unrelated but well characterised vaccine antigen TTd in the same individuals. 
On average, the magnitude of the IgG antibody response towards each of the P. falciparum 
antigens increased in both exposure groups until reaching a maximum after approximately 14 
days. After this, levels initially declined rapidly followed by a second phase of more slow 
decay. Geometric mean malaria-specific total IgG levels were consistently higher in 
individuals with prior malaria exposure for all antigens except MSP-3. The differences were 
particularly evident in the greater boost size and in the maintenance of higher plateau levels at 
the end of follow-up, where individuals with prior exposure maintained on average 2 to 9-
fold greater antibody levels than previously naïve individuals (Figure 11). 
 
Figure	11.	Model	predicted	antibody	dynamics.	The	geometric	mean	antigen-specific	total	IgG	levels	over	time	
for	malaria	antigens	and	TTd	in	each	exposure	group.	Solid	lines	denote	the	previously	exposed	while	dashed	
lines	denote	the	previously	malaria	naïve.	The	dotted	line	represents	the	assay	lower	limit	of	quantification.	 	
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The half-life of IgG antibody molecules varied slightly with antigen specificity and ranged 
from 13 to 21 days. The half-lives of short-lived ASC ranged from 9 to 16 days and were 
shortest for ASCs producing antibodies specific for MSP-3 while longest for ASCs producing 
antibodies to AMA-1 (Figure 8B). The half-life of malaria-specific long-lived ASCs ranged 
from 610 to 1368 days (i.e. 1.7-3.7 years) and tended to be shorter for schizont extract and 
MSP-119 while longer for MSP-3. The half-life of long-lived ASCs producing IgG to TTd 
was considerably long in comparison and was estimated to 2704 days, i.e. 7.4 years  
(95% CrI: 5-11.4 years). The contribution by malaria-specific long-lived ASCs to the overall 
antibody response was estimated to be greater in individuals with prior malaria exposure, 
where it ranged from 10 to 57% depending on antigen, than among previously naïve 
individuals where it was estimated to be less than 10% for all antigens. For TTd the 
proportion of long-lived (expected to be 100%) was estimated to 96% and thus consistent 
with a non-boosted antibody response (Figure 12). 
The dynamics of the IgG subclass responses were similar to those of the total IgG responses. 
Geometric mean antibody levels were consistently higher in previously exposed individuals 
for all antigens and IgG subclasses, except for IgG2 to MSP-119 for which there was no 
difference between groups. The differences were particularly evident in the IgG1 response to 
AMA-1 and in the IgG3 response to MSP-2 antigens, where previously exposed individuals 
maintained 15.5 to 21.5-fold and 14.1 to 31.1-fold greater levels at the end of follow-up, 
respectively. On average, only previously exposed individuals mounted a detectable IgG4 
response and although levels were low, difference in geometric mean levels were substantial 
across all antigen specificities. Furthermore, estimates of decay rates based on IgG1 and IgG3 
were similar to corresponding estimates based on total IgG. For IgG1 and IgG3, half-lives of 
long-lived ASCs ranged from 800 to 1424 days (i.e. 2.1-3.9 years). There was greater 
variability in half-lives of long-lived ASCs producing IgG2 and IgG4, for which estimates 
ranged from 729 to 2232 days (i.e. 2.0–6.1 years). Previously exposed individuals were 
estimated to have a greater contribution from long-lived ASCs for most subclass responses, 
however, there was substantial variability between subclasses and antigen specificities and 
the estimated proportion of long-lived ASCs ranged from 5% (95% CrI: 2 – 89) to 85% (95% 
CrI: 56 – 99). In previously naïve individuals, the estimated proportion of long-lived ASCs 
was similar across antigen specificities within each IgG subclass and ranged from 2% (95% 
CrI: 0 – 14) to 23% (95% CrI: 9 – 42).
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4.4 STUDY IV 
To identify novel candidate serological markers of recent and cumulative malaria exposure, 
we exploited the insights regarding antibody dynamics obtained from study III. We used a 
protein microarray approach to measure the antibody response to 111 P. falciparum blood-
stage antigens in 65 adult travellers (21 without and 44 with prior malaria exposure) followed 
longitudinally for one year in a malaria free country after a successfully treated P. falciparum 
infection.  
We identified 86 of the 111 tested antigens as immunoreactive in the cohort under study. 
Although the particular dynamics of the antibody response differed for each antigen, the 
majority of responses exhibited a substantial increase in magnitude after the acute infection, 
with a peak in the response around day 10, followed by a subsequent gradual loss of the 
response throughout the remainder of the follow-up period. Individuals with prior malaria 
exposure displayed greater magnitude and breadth of the response, in particular at the time of 
diagnosis. For MSP-1 and MSP-2 antigens, as well as MSP-4, MSP-10, AMA-1, EBA-175, 
and EBA181, individuals with prior exposure displayed a greater magnitude of the antibody 
response throughout the follow-up period, suggesting that the response to these antigens 
provide information on cumulative exposure. Antibody decay rates, estimated using linear 
mixed effects models, were antigen dependent and estimated to be highest for 
MSP2CH150/9DBL2, PF3D7_1136200, GAMA, MSP33D7, PF3D7_0206200, MSP8, and 
PTEX150 while lowest for PFA044W, CLAG3.2, RH2b, PFA0210c, and 
PF3D7_1460600(ISP3). The estimated half-lives of the response ranged from 129 days (95% 
CI: 113-150 days) for MSP2CHO150/9DBL2 to 795 days (95% CI: 425 – 6285 days) for 
PF0445w. The reactivity towards antigens for which the estimated half-lives were longest 
tended to be low. To evaluate whether the antibody responses to any of the antigens could be 
used to classify if a sample had been collected from an individual that had been recently 
infected (i.e. a recent infection defined as having occurred within 90 days of sample 
collection) we used binary classification based on logistic regression. First, we fitted 
univariable logistic regression classifiers to the antibody data for each antigen individually 
and compared the performance of the classifiers using cross-validated ROC analysis. In this 
univariable analysis the best classification performance was obtained using data for GAMA, 
PTEX150, PF3D7_1136200, and PfSEA-1, for which the cross-validated AUCs all exceeded 
0.8 (Figure 13). For a majority of responses, however, classification performance was 
relatively poor. 
We then proceeded to evaluate whether combining data on antibody responses for up to five 
antigens could improve the classification performance of the logistic regression classifier. 
Because there are 34,826,302 ways to select a combination of five antigens out of 86, we 
used a feature selection algorithm based on a random forest classifier to reduce the number of 
antibody responses to be evaluated. We limited our evaluation to antigens that were 
determined by the feature selection algorithm to contribute significantly to classification of 
whether or not an individual had been recently infected and identified 24 antigens that were 
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selected for further evaluation. We tested all possible two to five-way combinations of 
antibody responses to these 24 antigens. We found that combining information on the 
antibody response to more than one antigen provided limited improvement of overall 
classifier performance as indicated by minor increase in cross-validated AUC. The cross-
validated AUC of the best classifier increased from 0.83 to 0.84 with the sequential addition 
of up to five antibody responses. The best classifiers based on a combination of antibody 
responses all included the response to GAMA, however, these classifiers did not perform 
significantly better than a classifier based on the response to GAMA alone. 
 
 
Figure	13.	Antibody	responses	predictive	of	recent	infection.	Cross-validated	ROC-curves	of	classifier	
performance	for	binary	classifiers	based	on	antibody	data	for	each	of	the	86	immunoreactive	antigens.	
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5 DISCUSSION 
The studies presented within this thesis examine the temporal transmission patterns in a rural 
Tanzanian setting and present new methodology for the surveillance of infectious disease 
transmission. They also provide quantitative estimates of antibody dynamics, and characterise 
the broad specificity of the response following a single malaria infection. Together they 
contribute to our overall understanding of the acquisition and maintenance of the antimalarial 
antibody response and provide new information on how antibody responses to P. falciparum 
can be explored as markers of exposure. 
In study I, data and samples from cross-sectional surveys conducted within a longitudinally 
followed cohort in Nyamisati, a rural Tanzanian village, were analysed. Study I provides 
important long-term data on the temporal trends in P. falciparum prevalence within a closely 
monitored population and contributes to the understanding of the changing malaria 
prevalence in East Africa. We identified a substantial reduction in the prevalence of  
P. falciparum infection from 1985 to 2010. The findings are consistent with reports from 
across the African continent, including Tanzania, where the decline in transmission intensity 
after year 2000 has been largely attributed to increasing coverage of ITNs (5,205). However, 
in our cohort, a decline in P. falciparum prevalence preceded the introduction of ITNs, and 
started shortly after the arrival of the research team in 1985. Similar observations have been 
reported from elsewhere in Tanzania as well as from Kenya and Senegal (206–208). 
Although several factors may have contributed to this initial decline, it is likely that the 
presences of a research and healthcare team in the village made a considerable impact. This 
further highlights the importance of prompt diagnosis and treatment in order to limit malaria 
morbidity as well as transmission, as has been previously described (5,110,206–208). ITNs 
were introduced in Nyamisati village at large scale in 1999, after which malariometric 
monitoring ceased when the research team moved from the village. A new cross-sectional 
survey, conducted in 2010, revealed a substantial further decline in the prevalence of P. 
falciparum infection in Nyamisati. In addition, we identified a substantial reduction in the 
overall prevalence of anaemia during the study period, consistent with the reduction in 
malaria burden and possibly a general improvement of health status (36). The lack of 
surveillance between 1999 and 2010 makes it difficult to evaluate which factors may have 
contributed to the change in malaria burden. Between year 2000 and the beginning of 2010 
there was a substantial scale-up of the national malaria control efforts in Tanzania. This 
started with the introduction of IPTp in 2002, and was followed by a nation-wide distribution 
of ITN vouchers for pregnant women and infants beginning in 2004, the implementation of 
ACTs as first-line treatment from December 2006, and an expansion of the ITN program to 
under-fives in 2008 (205). However, the ITN campaigns did not reach Rufiji to any larger 
extent prior to 2010, and ACTs were not readily available in Nyamisati until 2009, and are 
thus not likely to have contributed substantially to the observed reduction in parasite 
prevalence between 1999 and 2010 (205).  
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 Studies conducted at several sites in the coastal area of the Tanga region, where organised 
vector control efforts were limited, report substantial changes in abundance and composition 
of the vector populations during the corresponding time period (209,210). Unfortunately no 
data on vector populations were collected in Nyamisati during the project. 
The long time intervals between the cross-sectional surveys and the absence of data on vector 
populations hinder efforts to elucidate the temporal transmission patterns and evaluate 
potential causes of the observed decline in parasite prevalence between 1999 and 2010. This 
highlights the need for alternative tools for surveillance in areas where only data from limited 
number of cross-sectional surveys are available (123,128,132). 
Cross-sectional data on age-specific antibody responses to P. falciparum antigens have 
successfully been used to evaluate temporal trends in malaria transmission (146,170,171) and 
antibody responses to Anopheles gambiae salivary gland protein 6 (gSG6) has been 
highlighted as a useful surrogate marker for malaria vector exposure (136,138). In study II, 
we aimed to improve serological methods for transmission monitoring based on cross-
sectional data by developing new antibody acquisition models which assume that the rate of 
increase in antibody levels with age can be used as an alternative marker of transmission 
intensity. Using both the previously validated serocatalytic models and the novel antibody 
acquisition models to further examine the transmission patterns in Nyamisati (described in 
study I) allowed us to compare their performance. Models were fitted to age-specific data on 
antibody responses to MSP-1, MSP-2, MSP-3, AMA-1, and gSG6 in 1-16 years old children 
participating in cross-sectional surveys conducted in 1999 and 2010. We demonstrated that 
the new antibody acquisition models, which avoid the loss of information that occurs when 
antibody levels are dichotomised, increased both the precision and power of transmission 
estimates (168). They enabled us to establish that a 72-92% stepwise decrease in transmission 
intensity occurring between 1997 and 2000 was likely to have been the single most important 
reduction event during the period under study. The serocatalytic models did not have the 
statistical power to determine whether a stepwise reduction in transmission was more likely 
than a continuous decline, and although similar point estimates for the time of change were 
obtained, these displayed considerable uncertainty. The estimated timing of the stepwise 
reduction in transmission intensity coincides roughly with the distribution of ITNs in 
Nyamisati that was conducted in 1999. Furthermore, the substantial reduction in both levels 
and prevalence of antibodies to gSG6 between 1999 and 2010 clearly indicated a reduction in 
vector exposure. However, the current modelling approach provided poor fit to the gSG6 data 
due to the absence of an age-trend in the antibody response. As demonstrated in study I, 
parasite prevalence in Nyamisati declined gradually during the 1990’s, and although several 
factors may have contributed to the low level of parasite and vector exposure in 2010, the 
results provide strong support of the largest single reduction in transmission intensity being 
related to the distribution of ITNs in 1999. The antibody acquisition models performed better 
than the corresponding serocatalytic models in the context of high to moderate transmission 
intensity in which study II was conducted. 
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In such a setting the sensitivity and precision of serocatalytic models often are limited by a 
long duration of seropositivity and therefore by saturation in seroprevalence already among 
children (211–213). In study II, it is likely that this phenomenon contributed to the 
uncertainty of the serocatalytic model parameter estimates. Antibody levels do not display an 
age-dependent saturation to the same extent and furthermore, antibody levels have been 
shown to decline rapidly when exposure is reduced (68,77,78,171,214). These two factors 
contribute to the additional power of the antibody acquisition models to detect transmission 
changes, in particular when transmission intensity is high (214). In contrast, serocatalytic 
models may be more useful when transmission is low because data on seropositivity for 
multiple antigens can easily be combined to improve sensitivity to detect seroconversion 
events (215). In study II, antibody responses to AMA-1 provided most precise parameter 
estimates and most consistent transmission estimates between the two modelling approaches. 
There was little saturation in antibody levels to AMA-1 with increasing age and antibody 
levels to each of the two allelic variants of AMA-1 were highly correlated. This suggests that 
AMA-1 may be suitable as a serological marker for monitoring of medium to long-term 
transmission trends in a wide range of transmission settings. 
The issue of parameter identifiability is a critical factor when modelling cross-sectional data 
on antibody responses to estimate the rate of seroconversion or antibody acquisition (216). 
This means that in cases where data are limited, it may be impossible to distinguish between a 
scenario in which individuals acquire and lose antibodies rapidly or the opposite in which 
antibodies are both acquired and lost slowly leading to unreliable estimates of transmission 
intensity (216). An additional challenge for serological surveillance, particularly in 
elimination settings, is the difficulty to differentiate recent from more distant exposure 
(132,217). Further improvement of serological tools for transmission monitoring therefore 
requires a better understanding of the factors that determine the acquisition and maintenance 
of the antimalarial antibody response. Reliable quantitative estimates of antigen specific 
antibody decay rates and identification of novel serological markers, or combinations of 
markers, that discriminate between recent or more distant exposure are also needed 
(132,217). 
In study III, we provided a detailed characterisation of the dynamics of the antibody response 
to P. falciparum vaccine candidate antigens (MSP-119, MSP-2, MSP-3, AMA-1 and RH5) 
after a single clinical malaria episode in complete absence of re-exposure by studying malaria 
exposed travellers followed prospectively for one-year after treatment in Sweden. We used 
mathematical modelling of antibody dynamics to provide quantitative estimates of the 
longevity of antibodies and antibody secreting cells. The breadth and magnitude of the 
response was, as expected, greater among individuals with prior malaria exposure. For a 
majority of the evaluated antigens, differences in the magnitude between exposure groups 
were particularly evident in levels of IgG1 and IgG3, which have previously been associated 
with protection from clinical disease (53,218–220).  
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A greater boosting of antibody levels, as was observed in previously exposed individuals, 
corresponds to the generation of a greater absolute number of short-lived ASCs. This was 
likely due to the presence of a previously established memory B-cell response, rapidly 
proliferating and differentiating into short-lived ASCs upon re-infection (69–71). 
When examining the antigen-specific total IgG response, we found that the half-lives of 
short-lived ASCs ranged from a few days to a few weeks, whereas the half-life of long-lived 
ASCs ranged from 2-4 years. These estimates were highly comparable with previous results 
from African children (68,77,78). Half-lives of IgG1 and IgG3 producing long-lived ASCs 
were similar to those estimated from the total IgG response, while estimates for long-lived 
ASCs producing IgG2 or IgG4 tended to be slightly longer. Interestingly, we found that 
individuals without prior malaria exposure did acquire long-lived ASCs following a primary 
malaria infection. However, in these individuals the numbers of acquired long-lived ASCs 
were relatively small and, in the case of total IgG responses, on average represented less than 
10% of the ASCs generated. We showed that individuals with prior exposure generated and 
maintained a larger number of long-lived ASCs. This was supported both by an overall 
higher proportion of ASCs that were long-lived and by the maintenance of higher antibody 
levels at the end of follow-up, reflecting maintenance of a greater absolute number of long-
lived ASCs. To provide a validation of the model structure and the reliability of model 
estimates, we fitted the same model to data on the dynamics of the response to tetanus toxoid 
in the same individuals. The longevity of the antibody response to TTd has been well 
characterised. We found that the estimated half-lives of long-lived tetanus-specific ASCs 
were highly consistent with previously published estimates (i.e. approximately 7-14 years) 
(74,221,222) and determined that this provided a validation of our model estimates for the  
P. falciparum antigens. 
Accumulating evidence suggests that the immune environment induced during a P. 
falciparum infection inhibits the development of a long-lived antibody response. This has 
been proposed to be mediated through a dysregulation of the B-cell response in which 
impaired T-cell help and germinal centre formation (80,81) leads to preferential induction of 
short-lived ASCs and the generation of so called atypical memory B-cells (57,68,82,83,223). 
In study III, we found that the half-life of long-lived ASCs specific for the evaluated malaria 
vaccine candidate antigens was notably short in comparison with that of long-lived tetanus 
specific ASCs. In addition, we also found the acquisition of long-lived ASCs following 
primary malaria infection to be low. 
Study III demonstrated that exposure dependent differences in antibody dynamics can be 
described by differences in the size of the antibody boost and the acquired proportion of long-
lived ASCs. In light of these results, we propose that the relatively short-lived nature of the 
naturally acquired antibody response following primary malaria infection could be attributed 
to a poor acquisition and short half-life of long-lived ASCs. Furthermore, we propose that 
more long-lived antibody responses are acquired over time with repeated infections by small 
consecutive additions to the pool of long-lived ASCs with each new infection.  
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This is supported by data from Ghana and the Gambia, where the proportion of long-lived 
ASCs in children was estimated to increase with age (68,77), and could also partly explain 
the observation of a more rapid seroreversion in children, compared to adults, in endemic 
areas following interruption of transmission (172). 
The results from study III contribute to our understanding of naturally acquired immune 
response to malaria and can be used to guide strategies for further development of both 
vaccines and serological tools to monitor exposure. To date a vast majority of successful 
vaccines against various infections induce protection mediated through antibodies that are 
maintained following just a few immunisations (101). Antibodies are likely to be important 
also for mediating protection in the context of a malaria vaccine (89). The findings in study 
III emphasise the importance of a vaccine response not only to mimic the naturally acquired 
immune response but also the need for a malaria vaccine to skew the humoral response 
towards generation of long-lived ASCs through improvement of delivery platforms, 
adjuvants and by optimisation of dosage and vaccine regimens (89). 
The quantitative estimates of the antibody dynamics presented in study III can be used to 
improve serological estimates of transmission intensity based on cross-sectional data on the 
response to these antigens. However, further improvement of serological tools for disease 
surveillance will require identification of antibody responses to novel target antigens that 
change predictably over time, regardless of the individual’s prior level of exposure. Data on 
the dynamics for such an antibody response can theoretically be exploited to estimate when 
the individual was last infected which would in turn allow for disease incidence to be 
estimated from cross-sectional antibody data (131). 
In study IV, we used a protein microarray containing 111 P. falciparum antigens with the aim 
to examine differences in the specificity and dynamics of the response related to prior 
exposure, to characterise the rate of antibody loss following clearance of infection and to 
evaluate the predictive performance of the tested antigens as serological markers of either 
cumulative or recent exposure. For several antigens, in particular AMA-1, MSP-1, MSP-2, 
MSP-4, MSP-10, EBA-175, and EBA-181, the magnitude of the antibody response was 
substantially and significantly greater throughout the follow-up period in individuals with 
prior malaria exposure. This suggest that these antigens to a larger extent induce a memory 
response in the form of memory B-cells and long-lived plasma cells (63,65,70). In line with 
previous findings, the exposure related differences in the response to these antigens further 
suggest they may be informative of an individual’s cumulative malaria exposure. This has 
been previously demonstrated for AMA-1, MSP-1, and MSP-2 (147,152,153), and to a lesser 
extent reported also for MSP-4, MSP-10, and EBA-181 (156,224,225). For a majority of the 
evaluated antigens, however, there were no significant differences in the magnitude of the 
response related to prior exposure.  
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Although we observed high levels of antibodies to several of these antigens, in particular 
towards GAMA, MSP-8, RAMA, PfSEA-1, PF3D7_1136200, PF3D7_0206200, and 
PTEX150, the response to these antigens did not appear to be maintained over time. This was 
further supported by the higher rate of antibody decay estimated for these antigens, 
suggesting a poor induction of a long-lived plasma cell  
response (68,86). 
Interestingly, there were overall substantial antigen dependent differences in the rate of 
antibody decay with estimated antibody half-lives ranging from 129 (95% CI: 113 – 150) to 
795 (95% CI: 425 – 6285) days. We identified antibody response to 24 P. falciparum 
antigens that, either independently or in combination, provided information on whether an 
individual had been infected within the last three months. Among these 24 antigens, only 
MSP-1, MSP-2, and MSP-10 had previously been brought forward as useful markers of 
exposure (146,217,226). The 24 antigens were selected for a more in depth evaluation. 
Through binary classification using logistic regression we determined that for single antigens 
the best prediction of recent exposure was achieved using data on the response to GAMA, 
PTEX150, PF3D7_1136200, or PfSEA-1, for which the cross-validated AUC of the binary 
classifiers exceeded 0.8. We further evaluated all possible combinations of antibody 
responses for up to five of the 24 selected antigens and found that combining data on the 
response to more than one of these antigens did not provide major improvements of the 
ability to predict a recent exposure. We found the response towards GPI-anchored 
micronemal antigen (GAMA), Plasmodium translocon of exported protein (PTEX150), 
PF3D7_1136200, and P. falciparum schizont egress antigen 1 (PfSEA-1) to be the most 
informative. We believe that the responses to these antigens show promise as candidate 
serological markers of recent malaria exposure and should be further evaluated. 
In summary, the studies presented within this thesis evaluate different methods to estimate 
malaria transmission intensity and examine multiple aspects of the antimalarial antibody 
response on both a population and individual level. The studies provide information that 
contributes to our understanding of the acquisition and maintenance of the antimalarial 
antibodies and will help improve serological methods for malaria surveillance. While many 
aspects of the antibody responses studied here are specific for malaria, the overall concepts 
are generally applicable with regards to antibody responses in infection. The results presented 
here may therefore provide guidance for future studies on antibody responses to other 
infectious diseases. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
• Parasite prevalence, measured by microscopy or PCR, is commonly used to estimate 
P. falciparum transmission but evaluation of spleen rate and haemoglobin levels 
remain useful complements to these methods for estimating the malaria burden in 
areas of intense transmission where infection prevalence is high. 
• Antibody acquisition models can improve precision in estimates of transmission 
intensity based on cross-sectional serological data, particularly in settings of moderate 
and high transmission intensity where seroprevalence is high. 
• Quantitative estimates of the immune parameters underlying the dynamics of the 
antibody response are imperative for understanding acquisition and maintenance of 
antibody-mediated immunity and for further improvement of serological methods for 
transmission surveillance. 
• The overall short-lived nature of the antibody response to natural malaria infection 
can be attributed to a combination of an inefficient acquisition and a short half-life of 
long-lived ASCs. 
• The dynamics of antimalarial antibody responses are antigen specific. For some 
antigens, a more long-lived response is acquired after repeated infections, while for 
others, this type of memory responses is not induced to the same extent. 
• Identification of novel serological markers of recent malaria exposure, which can be 
used to estimate the time since the last infection, would greatly improve transmission 
surveillance. Antibody responses to P. falciparum antigens GAMA, PfSEA-1, 
PF3D7_1136200, PTEX150 appear to be interesting candidate markers of recent 
malaria exposure that warrant further investigation. 
 
While several countries are currently experiencing a situation where malaria transmission has 
declined to the extent that malaria elimination appears achievable, others provide concerning 
reports of resurgence in transmission after years of positive trends. 
The most efficient way to further limit malaria transmission is likely through a highly 
effective vaccine. However, despite substantial efforts for development, such a vaccine 
remains elusive. The most advanced malaria vaccine to date, RTS,S, provides only partial 
protection and vaccine efficacy appears to wane quickly as antibody responses decline. 
Although our understanding of the antimalarial immune response to both natural infection 
and vaccination has improved significantly in recent years, the lack of reliable immunological 
correlates of protection hampers vaccine design efforts. Identification of correlates of 
protection would substantially accelerate vaccine discovery and should be explored through 
future studies taking a systems immunology, or systems serology, approach. These studies 
will need to simultaneously evaluate multiple immunological parameters by combining data 
on the magnitude as well as the functional aspects of the immune response.  
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Preferably these studies should also investigate the factors that cause the large inter-
individual variation in the immune response to both natural infection and vaccination. 
Independent of vaccine development, and irrespective of the current transmission situation, 
maintaining a robust system for disease surveillance is imperative in order to generate reliable 
information that can be used to prioritise resources for malaria control and limit transmission. 
As previously discussed, serology is a tool that could be useful and help improve malaria 
surveillance particularly in low transmission settings where the prevalence of infection is low, 
or in cases where data on disease incidence is limited or unreliable, as is often the case in 
malaria endemic areas. In order to make optimal use of serology as a tool for malaria 
transmission surveillance there is a need for identification of better and more reliable 
serological markers of exposure. However, any serological markers that appear informative 
in explorative analyses will need to be rigorously evaluated and validated to confirm their 
usefulness prior to implementation as a surveillance tool. Such a process will need to include 
careful evaluation of the candidate marker in cohort studies conducted in different 
geographical areas and different transmission intensity settings. 
If reliable serological markers can be identified and serology is to be implemented on a larger 
scale for coordinated surveillance of disease transmission, standardisation of the serological 
assays to be used is critical. This concerns the recombinant proteins used as antigens, as well 
as the assay procedures, and includes assuring that the measured quantities are comparable 
and reproducible across laboratories, platforms, and situations. To date, there have been some 
efforts to increase the degree of standardisation within the research community, e.g. through 
sharing of protocols and standard calibrator preparations between laboratories, and by WHO 
to provide a commercially available lyophilised malaria reference serum. However, common 
standards have not yet become widely adopted. Ideally the format of the immunoassay should 
also be adapted to allow for easy implementation in resource-poor settings without the need 
for access to more advanced laboratory equipment. This could be achieved e.g. by further 
development of a validated standard serological ELISA assay into a lateral flow 
immunoassay format. 
Monitoring and surveillance systems in countries approaching malaria elimination are facing 
new challenges. Tools suitable for monitoring of a disease that is endemic may not 
necessarily be useful in a near elimination setting or in a scenario where there is need to 
confirm that elimination has been achieved and is effectively maintained. In such a scenario 
the goal will not be to estimate the force of infection but rather to confirm interruption of 
transmission. This will require readjusting surveillance systems for this task as well as 
developing new tools that can provide robust estimates of the absence of transmission to 
support the process of malaria elimination. 
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